# Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

> **NCT02567396** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Estrogen Receptor Negative
- Head and Neck Squamous Cell Carcinoma
- HER2/Neu Negative
- Hormone-Resistant Prostate Cancer
- Metastatic Pancreatic Adenocarcinoma
- Progesterone Receptor Negative
- Solid Neoplasm
- Stage III Mesothelioma
- Stage IIIA Gastric Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Small Cell Lung Carcinoma
- Stage IIIB Gastric Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Small Cell Lung Carcinoma
- Stage IIIC Gastric Cancer
- Stage IIIC Ovarian Cancer
- Stage IV Mesothelioma
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Ovarian Cancer
- Stage IV Small Cell Lung Carcinoma
- Triple-Negative Breast Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT02567396
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2018-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Other- Protocol moved to Disapproved
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567396, "Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02567396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*